U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-0653
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Oncologist
Cancer ResearchMedicineOncology
2007English

Transparency and Dermatologic Device Approval by the US Food and Drug Administration

JAMA Dermatology
DermatologyMedicine
2018English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies

Archives of Internal Medicine
2011English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology
Hematology
2015English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy